Geode Capital Management LLC Has $3.72 Million Holdings in Kindred Biosciences Inc (KIN)

Share on StockTwits

Geode Capital Management LLC raised its stake in Kindred Biosciences Inc (NASDAQ:KIN) by 1.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 339,644 shares of the biopharmaceutical company’s stock after purchasing an additional 5,233 shares during the period. Geode Capital Management LLC’s holdings in Kindred Biosciences were worth $3,719,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. B. Riley Financial Inc. lifted its holdings in Kindred Biosciences by 75.0% in the third quarter. B. Riley Financial Inc. now owns 35,000 shares of the biopharmaceutical company’s stock valued at $488,000 after acquiring an additional 15,000 shares during the period. Morgan Stanley lifted its holdings in Kindred Biosciences by 0.3% in the third quarter. Morgan Stanley now owns 2,168,559 shares of the biopharmaceutical company’s stock valued at $30,251,000 after acquiring an additional 7,438 shares during the period. Meeder Asset Management Inc. lifted its holdings in Kindred Biosciences by 17.5% in the fourth quarter. Meeder Asset Management Inc. now owns 10,216 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 1,518 shares during the period. Bank of New York Mellon Corp lifted its holdings in Kindred Biosciences by 24.4% in the third quarter. Bank of New York Mellon Corp now owns 90,847 shares of the biopharmaceutical company’s stock valued at $1,267,000 after acquiring an additional 17,798 shares during the period. Finally, Strs Ohio lifted its holdings in Kindred Biosciences by 36.1% in the fourth quarter. Strs Ohio now owns 39,500 shares of the biopharmaceutical company’s stock valued at $432,000 after acquiring an additional 10,483 shares during the period. 56.80% of the stock is owned by institutional investors.

KIN has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Kindred Biosciences in a report on Monday, January 14th. BidaskClub raised Kindred Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, January 12th. Cantor Fitzgerald set a $25.00 price target on Kindred Biosciences and gave the company a “buy” rating in a report on Monday, January 14th. ValuEngine downgraded Kindred Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Finally, Lake Street Capital decreased their price target on Kindred Biosciences from $30.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Kindred Biosciences currently has a consensus rating of “Buy” and a consensus price target of $17.82.

Shares of NASDAQ:KIN opened at $9.34 on Friday. The company has a market capitalization of $344.26 million, a price-to-earnings ratio of -5.84 and a beta of 0.39. Kindred Biosciences Inc has a 12-month low of $8.04 and a 12-month high of $15.75.

Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings data on Wednesday, March 6th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.04). The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.44 million. Equities research analysts predict that Kindred Biosciences Inc will post -1.54 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Geode Capital Management LLC Has $3.72 Million Holdings in Kindred Biosciences Inc (KIN)” was originally reported by Highlight Press and is owned by of Highlight Press. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://highlightpress.com/2019/04/26/geode-capital-management-llc-has-3-72-million-holdings-in-kindred-biosciences-inc-kin.html.

Kindred Biosciences Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: Moving Average (MA)

Want to see what other hedge funds are holding KIN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kindred Biosciences Inc (NASDAQ:KIN).

Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.